ACADIA PHARMACEUTICALS INC (ACAD)       16.89  +0.61 (+3.75%)

16.89  +0.61 (+3.75%)

US0042251084 - Common Stock


Fundamental Rating

5

Overall ACAD gets a fundamental rating of 5 out of 10. We evaluated ACAD against 638 industry peers in the Biotechnology industry. Both the profitability and the financial health of ACAD get a neutral evaluation. Nothing too spectacular is happening here. ACAD is valued quite expensive, but it does show an excellent growth.




Profitability

Profitability Rating

5

ACAD has a Return On Assets of -33.39%. This is better than the industry average of -41.19%.
ACAD has a Profit Margin of -39.93%. This is amongst the best returns in the industry. The industry average is -408.39%. ACAD outperforms 81% of its industry peers.

ACAD has a Piotroski-F score of 5.00. This indicates an average health and profitability for ACAD.
The profitability ratios for ACAD are negative, so there is not much use analyzing them.
VS Industry

ROA (-33.39%) VS Industry: 64% outperformed.

-1,441.42
115.38

Profit Margin (-39.93%) VS Industry: 81% outperformed.

-1,173,705.71
8,610.80

Valuation

Valuation Rating

1

With a price book ratio of 6.29, ACAD is valued correctly.
The Price/Earnings Ratio is negative for ACAD. In the last year negative earnings were reported.

Also next year ACAD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
When comparing the price book ratio of ACAD to the average industry price book ratio of 1.62, ACAD is valued more expensive than its industry peers. 89% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (6.29) VS Industry: 11% outperformed.

171.17
0.09

Growth

Growth Rating

7

The Earnings Per Share has grown by an impressive 45.45% over the past year.
ACAD is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 15.15% yearly.
Looking at the last year, ACAD shows a quite strong growth in Revenue. The Revenue has grown by 10.57% in the last year.

Measured over the past 5 years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 94.71% on average per year.
The Revenue is expected to grow by 18.06% on average over the next 5 years. This is quite good.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 45.45% -25.52% 19.79% 29.54% 15.15%
Revenue94.71% 29.33% 10.57% 8.58% 13.19% 16.8% 18.06%

Health

Health Rating

6

ACAD has a Current Ratio of 4.53. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.47 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has an Altman-Z score of 4.43. This indicates that ACAD is financially healthy and little risk of bankruptcy at the moment.
ACAD is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of -0.10.

The Debt to Equity ratio of ACAD is in line with the industry averages.
ACAD has a Piotroski-F score of 5.00. This indicates an average health and profitability for ACAD.
When comparing the Current Ratio of ACAD to the average industry Current Ratio of 6.52, ACAD is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.48, ACAD is worse placed to pay its short term obligations than its industry peers.
VS Industry

Debt/Equity (0) VS Industry: 43% outperformed.

18.24
0.00

Quick Ratio (4.47) VS Industry: 36% outperformed.

0.03
399.16

Current Ratio (4.53) VS Industry: 35% outperformed.

0.08
401.12

Altman-Z (4.43) VS Industry: 74% outperformed.

-1,821.48
293.92

Dividend

Dividend Rating

0

ACAD does not give a dividend.

ACAD Daily chart

ACADIA PHARMACEUTICALS INC16.89

NASDAQ:ACAD (9/27/2022, 8:48:49 AM)+0.61 (+3.75%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-08 2022-08-08/amc Earnings (Next) 11-07 2022-11-07
Ins Owners 0.16% Inst Owners 94.53%
Market Cap 2.73B Analysts 70.77
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 5.33 P/B 6.29
EV/EBITDA -11.15
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 45.45% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 22.22%
EPS Next Y -25.52% EPS Next 2Y 19.79%
EPS Next 3Y 29.54% EPS Next 5Y 15.15%
Revenue growth 1Y 10.57% Revenue growth 3Y 29.33%
Revenue growth 5Y 94.71% Revenue growth Q2Q 16.79%
Revenue Next Year 8.58% Revenue Next 2Y 13.19%
Revenue Next 3Y 16.8% Revenue Next 5Y 18.06%
Health
Current Ratio 4.53 Quick Ratio 4.47
Altman-Z 4.43 F-Score 5
Debt/Equity 0
Profitability
ROA -33.39% ROE N/A
ROIC N/A ROICg N/A
PM -39.93 OM -40.32
Asset Turnover 0.84

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA